There is no ICD-10 code for Cancer related cognitive impairment. ICD-10 coding is therefore based on the underlying disease, which differs depending on the underlying malignancy in each case. Cancer-related fatigue: no specific ICD-10 code is available for this either
Conditions
Interventions
Group 1: Ambulatory patients (curatively treated patients after completion of therapy and palliative treated patients in a stable disease situation for at least 6 months) are informed about the study
Sponsors
Universitätsklinikum Hamburg-Eppendorf
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients with cognitive impairment that developed in the context of cancer and its treatment. Completion of antitumor therapy (chemotherapy, immunotherapy, TKI, antibody therapy, and/or radiotherapy) at least 3 months and no longer than 5 years prior to inclusion into the study. In case of a continuous therapy (e.g. anti-hormonal therapy for breast cancer), this should have been started at least 3 months before inclusion into the study. At the time of study inclusion, it must be expected that no further antitumor therapy measures will be started within the next 6 months Age = 18 years and < 80 years Available access to the internet as well as access to a PC, laptop, or tablet Understanding of the German language, both written and spoken Willingness to participate in an MBSR study/present written informed consent
Exclusion criteria
Exclusion criteria: Pre-existing cognitive dysfunction which is not related to malignant disease. Tumor diseases associated with the central nervous system (e.g., malig-nant gliomas, cerebral metastases).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome: FACT-COG The outcomes are collected pseudonymously online. In the therapy group directly before the start of the MBSR course (T0), directly after completion of the course (T1) and after 3 months as follow-up (T2). In the waiting list control group directly before the start of the eight-week waiting period (T0), after eight weeks directly before the start of the then following MBSR course (T1), directly after completion of the course (T2) and after 3 months as follow-up (T3). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondrary outcome: FACT-G, BFI, PHQ-9 and neuropsychological tests (Go-No-Test; verbal learning and memory test) The outcomes are collected pseudonymously online. In the therapy group directly before the start of the MBSR course (T0), directly after completion of the course (T1) and after 3 months as follow-up (T2). In the waiting list control group directly before the start of the eight-week waiting period (T0), after eight weeks directly before the start of the then following MBSR course (T1), directly after completion of the course (T2) and after 3 months as follow-up (T3). | — |
Countries
Germany
Contacts
Public ContactAlena Krause
Universitätsklinikum Hamburg-Eppendorf Universitäres Cancer Center Hamburg (UCCH)
Outcome results
None listed